2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司核算的 会计科目 | 2025年期初占 用资金余额 | 2025年半年度占 用累计发生金额 | 2025年半年度 占用资金的利 | 2025年半年度 偿还累计发生 | 2025年半年度 期末占用资金 | 占用形成原因 | 是否披露 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | （不含利息） | 息(如有） | 金额 | 余额 | | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | | - | | 其他关联方及附属企业 | | | | | | | | ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司 2025 年半年度报告全文及摘要已于 2025 年 8 月 29 日在中国证监会指定的创业板信息披露网站(巨潮资讯网，网址： www.cninfo.com.cn)上披露，请投资者注意查看。 特此公告。 包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司 关于 2025 年半年度报告披露提示性公告 董事会 2025 年 8 月 29 日 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-056 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 第九届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、包头东宝生物技术股份有限公司(以下简称"公司")第九届董事会第十 二次会议通知于 2025 年 8 月 18 日以直接送达或电子邮件等方式通知了全体董事、 高级管理人员。 6、本次会议的召集、召开和表决程序符合法律、行政法规、部门规章、规 范性文件和公司《董事会议事规则》、《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 与会董事认真审阅了有关议案并进行了表决。经与会董事一致同意，形成决 议如下： 1、审议通过了《2025 年半年度报告全文及摘要》 经审议，董事会认为：公司 2025 年半年度报告全文及摘要真实、准确、完 整地反映了公司 2025 年半年度的实际经营情况，不存在任何虚假记载、误导性 陈述或重大遗漏，报告编制和审核程 ...

包头东宝生物技术股份有限公司 信息披露事务管理制度 (2025 年 8 月) 第一章 总则 第一条 为规范包头东宝生物技术股份有限公司（以下简称"公司"）信息 披露行为，促进公司依法规范运作，确保公司信息披露的真实、准确、完整与及 时，切实维护公司股东、债权人及其利益相关人的合法权益，依据《中华人民共 和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称 《证券法》）、《上市公司信息披露管理办法》、《上市公司治理准则》等规定 及《深圳证券交易所创业板股票上市规则》（以下简称《上市规则》）、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《公 开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》、 《包头东宝生物技术股份有限公司章程》（以下简称《公司章程》）的有关规定， 制定本制度。 第二条 本制度所称"信息"是指可能对公司证券及其衍生品种交易价格 或者投资决策产生较大影响的信息或事项，以及中国证监会及其派出机构、深圳 证券交易所要求披露的信息；本制度所称"披露"是指在规定的时间内、在指定 的媒体上、以规定的方式向社会公众公布前述信息，并按规 ...

Financial Performance - The company's operating revenue for the reporting period was CNY 369,055,800.99, a decrease of 16.93% compared to CNY 444,275,439.67 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 36,967,330.23, down 28.00% from CNY 51,341,802.92 year-on-year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 33,435,102.10, a decrease of 27.41% compared to CNY 46,062,959.25 in the previous year[23]. - The net cash flow from operating activities was CNY 50,292,504.65, down 16.37% from CNY 60,138,978.92 in the same period last year[23]. - Basic earnings per share were CNY 0.0629, a decline of 27.28% from CNY 0.0865 in the previous year[23]. - Diluted earnings per share were CNY 0.0579, down 26.71% from CNY 0.0790 year-on-year[23]. - The weighted average return on net assets was 2.14%, a decrease of 0.91% compared to 3.05% in the previous year[23]. - Total assets at the end of the reporting period were CNY 2,576,371,394.20, a decrease of 1.85% from CNY 2,624,919,556.21 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were CNY 1,705,824,856.12, down 1.94% from CNY 1,739,542,623.39 at the end of the previous year[23]. Dividend and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has repurchased a total of 10,573,400 shares, accounting for 1.7812% of the current total share capital, as part of its commitment to shareholder returns[44]. Market and Industry Insights - The Chinese nutritional health food retail market exceeded USD 37 billion in 2023, with a compound annual growth rate of 7.0% over the past three years, expected to maintain a growth rate of 6.2% in the next three years[33]. - The pharmaceutical industry is projected to maintain an average annual growth rate of over 8% during the 14th Five-Year Plan period, indicating strong market potential[31]. - The company is positioned to benefit from increasing consumer awareness of health and wellness, with a growing demand for collagen in nutrition and beauty products[32]. - The market for gelatin capsules, primarily made from gelatin, is closely tied to the development of the pharmaceutical industry, presenting opportunities for growth[31]. Product Development and Innovation - The company focuses on the development of "natural collagen" and aims to become a comprehensive enterprise group in the health industry, covering medical, beauty, health, and food sectors[30]. - The company has launched plasma gelatin, which is expected to expand its application in the medical field, including hemostatic materials and drug delivery systems[34]. - The company is focusing on the collagen industry strategy, with a new product "Beyou Mianpai Collagen Protein Vitamin C Powder" receiving market approval and being launched[43]. - The company is actively expanding its product matrix into new application areas, with several R&D projects making substantial progress and resulting in multiple patents[43]. - The company has established a comprehensive product layout in the collagen industry, enhancing its competitive advantage through product innovation and quality improvement[30]. - The company has made significant progress in R&D, including a low-endotoxin gelatin project with endotoxin levels reduced to below 30 EU/g[46]. - The company has launched new products in the health food sector, including collagen peptide powders and solid beverages, expanding its product offerings[51]. Financial Management and Investments - The company reported a significant increase in financial expenses by 130.74%, primarily due to increased interest expenses and decreased interest income[60]. - The company has established stable partnerships with major pharmaceutical companies, enhancing its market position and brand influence[56]. - The company plans to expand its global market presence while continuing to leverage its brand advantages and technological innovations[58]. - The company has cumulatively used CNY 278,316,118.82 of the raised funds, with CNY 160,859,104.04 allocated for permanent working capital[80]. - The company raised a total of RMB 455 million through the issuance of 4,550,000 convertible bonds, with a net amount of RMB 442.26 million after deducting issuance costs[81]. Operational Efficiency and Management - The company is implementing measures to improve operational efficiency and management effectiveness, focusing on shareholder rights and steady share repurchase[43]. - The company is enhancing its supply chain resilience by optimizing procurement strategies and establishing a dynamic supplier management system[43]. - The company is focusing on digital transformation to improve management efficiency and cost control, enhancing market competitiveness[49]. - The company is committed to enhancing the quality and safety of its products in response to increasing consumer demands for high-quality health products[36]. Regulatory and Compliance - The company has established a comprehensive quality management system, successfully passing regulatory inspections and customer audits during the reporting period[49]. - The company has received multiple certifications, including BRCGS and ISO9001, indicating its commitment to quality management and safety standards[52]. - Regulatory risks are increasing in the healthcare and nutrition sectors, necessitating the company's active participation in industry standards and compliance management[104]. Strategic Partnerships and Collaborations - The company is deepening collaborations with leading enterprises in the industry, resulting in further growth in export business[44]. - The company is focusing on strategic partnerships with high-quality production enterprises to promote the "Yuan Su" series of new products, enhancing market responsiveness[87]. Employee Engagement and Corporate Governance - Employee welfare is prioritized, with initiatives for health checks and cultural activities to enhance workplace environment and employee engagement[118]. - The company emphasizes the protection of shareholder and creditor rights by enhancing corporate governance and internal control systems, ensuring high-quality information disclosure[116]. Future Outlook - The company plans to expand its market presence by launching two new products in Q3 2025, targeting a 10% increase in market share[200]. - The future outlook remains positive, with projected revenue growth of 10% for the next half-year, driven by new product launches and market expansion[200].

Core Insights - Dongbao Bio is showcasing its self-developed medical blood plasma gelatin product, which has been included in the national list of innovative consumer goods, promoting import substitution in the biomedicine and regenerative medicine sectors [2] - The establishment of a "Technology Empowerment Party Building Alliance" aims to explore new development paths through the integration of party building and business operations [4] Group 1 - The automated production line at Dongbao Bio is operating efficiently, demonstrating the company's commitment to technological innovation in the biopharmaceutical field [2] - The alliance has gathered several high-tech enterprises and research institutions, including Shanghai Jiao Tong University Baotou Materials Research Institute, to facilitate resource sharing and collaborative activities [4] - The local government has introduced eight measures to accelerate technological innovation, including special funding for project support, which has led to a patent signing amount exceeding 320 million yuan and a total of 7,279 effective patents [6]

Group 1 - Dongbao Biological (300239) closed at 6.04 yuan on August 19, 2025, with a 0.5% increase and a turnover rate of 2.77% [1] - The company reported a total revenue of 188 million yuan for Q1 2025, a year-on-year decrease of 22.23%, and a net profit attributable to shareholders of 19.04 million yuan, down 26.64% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 4.494 and a quick ratio of 3.112, while the debt-to-asset ratio stands at 33.71% [1] Group 2 - Dongbao Biological has made investments in 8 companies and participated in 43 bidding projects [2] - The company holds 169 trademark registrations and 48 patents, along with 73 administrative licenses [2]

Group 1 - The company Dongbao Biological announced on August 1 that it has repurchased a total of 10,573,400 shares through a special securities account via centralized bidding, which accounts for 1.7812% of the company's current total share capital [2]

Group 1 - The stock price of Dongbao Biological (300239) closed at 6.13 yuan on August 1, 2025, with an increase of 2.34% and a turnover rate of 8.42% [1] - The company reported a total revenue of 188 million yuan for Q1 2025, a year-on-year decrease of 22.23%, and a net profit attributable to shareholders of 19.04 million yuan, down 26.64% year-on-year [1] - Dongbao Biological has a current ratio of 4.494, a quick ratio of 3.112, and a debt-to-asset ratio of 33.71% [1] Group 2 - Dongbao Biological has made investments in 8 companies and participated in 43 bidding projects [2] - The company holds 169 trademark registrations and 49 patents, along with 60 administrative licenses [2]

Group 1 - The company Dongbao Biological (300239.SZ) announced a share buyback program, having repurchased a total of 10,573,400 shares as of July 31, 2025, which represents 1.7812% of its current total share capital [1] - The highest transaction price during the buyback was 5.71 CNY per share, while the lowest was 4.59 CNY per share [1] - The total amount spent on the share buyback reached 56.11 million CNY, excluding transaction fees [1]